Advanced search
1 file | 201.19 KB Add to list

Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?

(2015) MELANOMA RESEARCH. 25(4). p.357-361
Author
Organization
Keywords
indoleamine 2, programmed-death ligand-1, 3-dioxygenase, negative feedback mechanism, adjuvant interferon-, melanoma, SENTINEL LYMPH-NODES, INDOLEAMINE 2, 3-DIOXYGENASE, INTERFERON-ALPHA, DENDRITIC CELLS, CUTANEOUS MELANOMA, SUPPRESSOR-CELLS, TRYPTOPHAN, INFLAMMATION, EXPRESSION, CORRELATE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 201.19 KB

Citation

Please use this url to cite or link to this publication:

MLA
CHEVOLET, INES et al. “Systemic Immune Changes Associated with Adjuvant Interferon-α2b-therapy in Stage III Melanoma Patients: Failure at the Effector Phase?” MELANOMA RESEARCH 25.4 (2015): 357–361. Print.
APA
CHEVOLET, I., Schreuer, M., Speeckaert, R., Neyns, B., Hoorens, I., van Geel, N., Kruse, V., et al. (2015). Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase? MELANOMA RESEARCH, 25(4), 357–361.
Chicago author-date
CHEVOLET, INES, Max Schreuer, Reinhart Speeckaert, Bart Neyns, Isabelle Hoorens, Nanja van Geel, Vibeke Kruse, et al. 2015. “Systemic Immune Changes Associated with Adjuvant Interferon-α2b-therapy in Stage III Melanoma Patients: Failure at the Effector Phase?” Melanoma Research 25 (4): 357–361.
Chicago author-date (all authors)
CHEVOLET, INES, Max Schreuer, Reinhart Speeckaert, Bart Neyns, Isabelle Hoorens, Nanja van Geel, Vibeke Kruse, Benjamin Hennart, Delphine Allorge, Mireille Van Gele, and Lieve Brochez. 2015. “Systemic Immune Changes Associated with Adjuvant Interferon-α2b-therapy in Stage III Melanoma Patients: Failure at the Effector Phase?” Melanoma Research 25 (4): 357–361.
Vancouver
1.
CHEVOLET I, Schreuer M, Speeckaert R, Neyns B, Hoorens I, van Geel N, et al. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase? MELANOMA RESEARCH. 2015;25(4):357–61.
IEEE
[1]
I. CHEVOLET et al., “Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?,” MELANOMA RESEARCH, vol. 25, no. 4, pp. 357–361, 2015.
@article{7224031,
  author       = {CHEVOLET, INES and Schreuer, Max and Speeckaert, Reinhart and Neyns, Bart and Hoorens, Isabelle and van Geel, Nanja and Kruse, Vibeke and Hennart, Benjamin and Allorge, Delphine and Van Gele, Mireille and Brochez, Lieve},
  issn         = {0960-8931},
  journal      = {MELANOMA RESEARCH},
  keywords     = {indoleamine 2,programmed-death ligand-1,3-dioxygenase,negative feedback mechanism,adjuvant interferon-,melanoma,SENTINEL LYMPH-NODES,INDOLEAMINE 2,3-DIOXYGENASE,INTERFERON-ALPHA,DENDRITIC CELLS,CUTANEOUS MELANOMA,SUPPRESSOR-CELLS,TRYPTOPHAN,INFLAMMATION,EXPRESSION,CORRELATE},
  language     = {eng},
  number       = {4},
  pages        = {357--361},
  title        = {Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?},
  url          = {http://dx.doi.org/10.1097/CMR.0000000000000171},
  volume       = {25},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: